Participated · Equity · Dec 2023

TokWise, founded in 2018, provides an AI-powered SaaS platform that links physical renewable assets directly to power exchanges. The platform enables power producers, green suppliers, commercial and industrial prosumers, aggregators and traders to control electricity purchases and sales and reduce risk in volatile markets. TokWise has built a data science team to develop algorithms that allow complete automation of power trading decisions. Its product addresses increased market volatility driven by higher shares of renewable generation by matching production and consumption. The company says the latest investment will expand its access to new markets and increase exposure across the EU. Strategic partnerships with investors are expected to bring industry knowledge and market access to accelerate growth.

Participated · Series B · Dec 2022

STORM Therapeutics is a clinical-stage biotech headquartered in Cambridge, UK, led by CEO Jerry McMahon. Its lead candidate, STC-15, is an oral small-molecule inhibitor of METTL3 and is described as the first RNA‑modifying enzyme inhibitor to enter human clinical trials. STC-15 is currently being assessed as a monotherapy in a Phase 2 study for selected sarcoma indications, and the company has reported dosing the first patient in that study. In April 2026 STORM raised $56M in a Series C to support advancement of STC-15 and to enhance the Phase 2 program. The company’s core focus is developing therapies that target RNA modifications to reprogram malignant cells.

Led · Seed · Jun 2021

2Parts is a Bulgarian document-management AI startup co-founded by Ivelin Ivanov and Lazar Draganov that uses computer vision and OCR to extract data from invoices, contracts, receipts, and bank statements. Its primary product, UNAC, is a SaaS document-processing tool that analyzes document structure and imitates human sight to improve speed and precision of data extraction. A second product, DOCRAI, is a PaaS OCR platform still in development and offers export formats for third-party accounting software. 2Parts emphasizes handling non-standard Bulgarian documents and is the first to offer a solution that processes Cyrillic for Bulgarian businesses. The company has been on the market for one year and initially funded development through bootstrapping and client revenue. It has strategic partnerships with Microinvest for market verification and with RPA Consulting on process automation integrations. 2Parts plans to expand its technology into law, insurance, logistics, banking and warehousing, adapt the software to other languages, enter regional markets, and boost marketing and client onboarding.

Led · Equity · Oct 2016

Kayentis provides electronic Clinical Outcome Assessment (eCOA) and decentralized/hybrid clinical trial (DCT) solutions to pharma, biotech and CROs. Led by CEO Guillaume Juge and active since 2003, the company supports phases II/III across a broad range of therapeutic areas and has expanded its services beyond eCOA to meet decentralized trial needs. Kayentis has conducted digital data collection for over 280 clinical trials in 85 countries, covering 18,000 sites and 98,000 patients in 120 languages, and employs 185 staff. It maintains offices in Boston, Grenoble and Tokyo and reports that U.S.-based sponsor teams lead about one-third of its projects. The company raised an additional €5M—€2.2M as increased capital from LBO France, Extens and Bpifrance and €2.8M in bank loans—to support growth. Kayentis intends to use the funds to scale up its North American operations to support clinical trials. Kayentis provides digital data capture technologies and eCOA solutions for sponsors, sites and patients in clinical trials, with a focus on phase II/III research. The company has been active in clinical development since 2003 and has specialized in eCOA over the past ten years while expanding into hybrid and decentralized trials. Its core product is the Clin’form3 eCOA platform, which Kayentis is enriching with new functions and apps to integrate with other clinical databases and adapt to clinical workflows. Kayentis has conducted digital data collection for over 220 clinical trials in 79 countries, covering 13,000 sites, 80,000 patients and 120 languages. Headquartered in Grenoble, France, the company also has operations in Boston and Tokyo and is led by CEO Guillaume Juge. The company plans to improve patient and site experience through televisits, eConsent and wearable integrations and to intensify US development. Kayentis develops electronic clinical outcome assessment (eCOA) solutions delivered via web portals and mobile tools, including patient-reported, clinician-reported, and observer-reported outcomes, automatic remote testing, and patient diaries. The company emphasizes patient engagement to improve data quality, compliance, and trial efficiency. It is a seven-year-old French firm whose platform has been used in more than 120 trials across 75 countries, impacting roughly 50,000 patients. Kayentis raised $3.9 million (3.6 million euros) in the reported funding round to support its growth. Management says the financing validates its development model and growth prospects and will fund continued platform improvements and value-added services. The company plans to use the funds to accelerate international expansion and to grow its sales, marketing, and R&D teams.

Led · Equity · Sep 2016

H4D develops telemedicine solutions centered on the Consult Station, a connected doctor’s office that enables secure videoconference consultations and physiological check-ups. The Consult Station is equipped with a comprehensive set of medical instruments (blood pressure monitor, thermometer, oximeter, stethoscope, EKG, glucometer) allowing physicians to perform remotely the majority of procedures for acute and chronic illnesses, including early detection, diagnosis, prescription and follow-up. The company’s solutions are used by corporate clients, local authorities, health insurance companies, hospitals and retirement homes across France, Europe, Africa and North America. Founded in 2008 by Dr Franck Baudino and based in Paris and Aix en Provence, H4D completed a second round of financing in 2016. The company intends to use the €6.7M to accelerate commercial rollout of its telemedicine services and to expand into several attractive markets in France and internationally.